Role of neuroimaging in children with acute lymphoblastic leukemia and central nervous system involvement at diagnosis

Ranta, Susanna; Palomäki, Maarit; Levinsen, Mette; Taskinen, Mervi; Abrahamsson, Jonas; Mellgren, Karin; Niinimäki, Riitta; Schmiegelow, Kjeld; Heyman, Mats; Harila‐Saari, Arja

doi:10.1002/pbc.26182

Cited by 51 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Controls were matched on birth year, sex, and maternal self-reported race/ethnicity. Detailed characteristics of these subjects have been reported previously 26 and appear in Supplementary Table 1.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic determinants of childhood and adult height associated with osteosarcoma risk

Zhang

Morimoto

Smith

et al. 2018

Cancer

View full text Add to dashboard Cite

Background: Although increased height has been associated with osteosarcoma risk in previous epidemiologic studies, the relative contribution of stature during different developmental time-points remains unclear. Furthermore, how genetic determinants of height impact osteosarcoma etiology remains unexplored. Genetic variants associated with stature in previous genome-wide association studies may be biomarkers of osteosarcoma risk. Methods: We tested the associations between osteosarcoma risk and polygenic scores for adult height (416 variants), childhood height, (six variants), and birth length (five variants) in 864 osteosarcoma patients and 1879 controls of European ancestry. Results: Each standard deviation increase in the polygenic score for adult height, corresponding to a 1.7-cm increase in stature, was associated with a 1.10-fold increase in risk of osteosarcoma (95% CI: 1.01–1.19, P= 0.027). Each standard deviation increase in the polygenic score for childhood height, corresponding to a 0.5-cm increase in stature, was associated with a 1.10-fold increase in risk of osteosarcoma (95% CI: 1.01–1.20, P= 0.023). The polygenic score for birth length was not associated with osteosarcoma risk (P=0.11). When adult and childhood height scores were modeled together, they were independently associated with osteosarcoma risk (P=0.037 and 0.043, respectively). An eQTL for CILP2 (cartilage intermediate layer protein 2), rs8103992, was significantly associated with osteosarcoma risk after adjustment for multiple comparisons (OR=1.35, 95% CI: 1.16–1.56, P=7.93×10−5, Padjusted=0.034). Conclusions: Genetic propensity to taller adult and childhood height attainments contributed independently to osteosarcoma risk in our data. These results suggest that the biological pathways affecting normal bone growth may be involved in osteosarcoma etiology.

show abstract

Section: Methodsmentioning

confidence: 99%

“…We also conducted case-only analyses, assessing whether polygenic scores for height were associated with differences in clinical presentation, including age at diagnosis, tumor location, and presence of metastasis. Clinical data were available for only the California cases and are coded as previously described 26 .…”

Section: Methodsmentioning

confidence: 99%

Genetic determinants of childhood and adult height associated with osteosarcoma risk

Zhang

Morimoto

Smith

et al. 2018

Cancer

View full text Add to dashboard Cite

show abstract

“…The inheritance of at least 1 B haplotype was determined by the expression of specific activating KIR genes and 1 inhibitory KIR as determined by the gene–gene model that are not components of the group A haplotypes. Haplotype B donors were preferred over haplotype A donors based on data obtained in our hematologic malignancy population [42] and previously published data [43–46] that KIR haplotype B donors improve progression-free survival (PFS) [45,47–53]. KIR haplotype B donors were identified for 14 of 16 patients.…”

Section: Methodsmentioning

confidence: 99%

Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients

Llosa

Cooke

Chen

et al. 2017

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

High-risk, recurrent, or refractory solid tumors in pediatric, adolescent, and young adult (AYA) patients have an extremely poor prognosis despite current intensive treatment regimens. We piloted an allogeneic bone marrow transplant platform using reduced-intensity conditioning (RIC) and partially HLA-mismatched (haploidentical) related donors for this population of pediatric and AYA solid tumor patients. Sixteen patients received fludarabine, cyclophosphamide, melphalan, and low-dose total body irradiation RIC haploidentical BMT (haploBMT) followed by post-transplantation cyclophosphamide (PTCy), mycophenolate mofetil, and sirolimus. All assessable patients were full donor chimeras on day 30 with a median neutrophil recovery of 19 days and platelet recovery of 21 days. One patient (7%) exhibited secondary graft failure associated with concomitant infection. The median follow-up time was 15 months. Overall survival was 88%, 56%, and 21% at 6, 12, and 24 months, respectively. Median survival from transplant date was 14 months with a median progression-free survival 7 months. We observed limited graft-versus-host disease in 3 patients and nonrelapse mortality in 1 patient. We demonstrated that RIC haploBMT with PTCy is feasible and has acceptable toxicities in patients with incurable pediatric and AYA solid tumors; thus, this approach serves as a platform for post-transplant strategies to prevent relapse and optimize progression-free survival.

show abstract

“…Wilson et al20) reported the results from a genome-wide association analysis of patients who had survived ALL treatment, and found several single nucleotide polymorphisms associated with obesity and cranial irradiation. Other attempts to find genetic differences among childhood leukemia survivors are ongoing51721).…”

Section: Characteristics Of Metabolic Syndrome In Cancer Survivorsmentioning

confidence: 99%

Metabolic syndrome induced by anticancer treatment in childhood cancer survivors

Chueh

Yoo

2017

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

The number of childhood cancer survivors is increasing as survival rates improve. However, complications after treatment have not received much attention, particularly metabolic syndrome. Metabolic syndrome comprises central obesity, dyslipidemia, hypertension, and insulin resistance, and cancer survivors have higher risks of cardiovascular events compared with the general population. The mechanism by which cancer treatment induces metabolic syndrome is unclear. However, its pathophysiology can be categorized based on the cancer treatment type administered. Brain surgery or radiotherapy may induce metabolic syndrome by damaging the hypothalamic-pituitary axis, which may induce pituitary hormone deficiencies. Local therapy administered to particular endocrine organs directly damages the organs and causes hormone deficiencies, which induce obesity and dyslipidemia leading to metabolic syndrome. Chemotherapeutic agents interfere with cell generation and growth, damage the vascular endothelial cells, and increase the cardiovascular risk. Moreover, chemotherapeutic agents induce oxidative stress, which also induces metabolic syndrome. Physical inactivity caused by cancer treatment or the cancer itself, dietary restrictions, and the frequent use of antibiotics may also be risk factors for metabolic syndrome. Since childhood cancer survivors with metabolic syndrome have higher risks of cardiovascular events at an earlier age, early interventions should be considered. The optimal timing of interventions and drug use has not been established, but lifestyle modifications and exercise interventions that begin during cancer treatment might be beneficial and tailored education and interventions that account for individual patients' circumstances are needed. This review evaluates the recent literature that describes metabolic syndrome in cancer survivors, with a focus on its pathophysiology.

show abstract

Role of neuroimaging in children with acute lymphoblastic leukemia and central nervous system involvement at diagnosis

Cited by 51 publications

References 20 publications

Genetic determinants of childhood and adult height associated with osteosarcoma risk

Genetic determinants of childhood and adult height associated with osteosarcoma risk

Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients

Metabolic syndrome induced by anticancer treatment in childhood cancer survivors

Contact Info

Product

Resources

About